Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Michael S. Seaman, Ph.D.

Co-Author

This page shows the publications co-authored by Michael Seaman and Dan Barouch.
Connection Strength

7.154
  1. Passive transfer of Ad26.COV2.S-elicited IgG from humans attenuates SARS-CoV-2 disease in hamsters. NPJ Vaccines. 2022 Jan 10; 7(1):2.
    View in: PubMed
    Score: 0.245
  2. Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial. Nat Med. 2021 10; 27(10):1718-1724.
    View in: PubMed
    Score: 0.241
  3. Correlates of Neutralization against SARS-CoV-2 Variants of Concern by Early Pandemic Sera. J Virol. 2021 06 24; 95(14):e0040421.
    View in: PubMed
    Score: 0.236
  4. Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19. JAMA. 2021 04 20; 325(15):1535-1544.
    View in: PubMed
    Score: 0.233
  5. Passive Transfer of Vaccine-Elicited Antibodies Protects against SIV in Rhesus Macaques. Cell. 2020 10 01; 183(1):185-196.e14.
    View in: PubMed
    Score: 0.224
  6. Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trial. Lancet Infect Dis. 2020 09; 20(9):1061-1070.
    View in: PubMed
    Score: 0.218
  7. Differential Outcomes following Optimization of Simian-Human Immunodeficiency Viruses from Clades AE, B, and C. J Virol. 2020 05 04; 94(10).
    View in: PubMed
    Score: 0.218
  8. Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22). Lancet HIV. 2020 06; 7(6):e410-e421.
    View in: PubMed
    Score: 0.215
  9. Similar Epitope Specificities of IgG and IgA Antibodies Elicited by Ad26 Vector Prime, Env Protein Boost Immunizations in Rhesus Monkeys. J Virol. 2018 08 01; 92(15).
    View in: PubMed
    Score: 0.192
  10. Neutralizing Antibody Responses following Long-Term Vaccination with HIV-1 Env gp140 in Guinea Pigs. J Virol. 2018 07 01; 92(13).
    View in: PubMed
    Score: 0.191
  11. Therapeutic Efficacy of Vectored PGT121 Gene Delivery in HIV-1-Infected Humanized Mice. J Virol. 2018 04 01; 92(7).
    View in: PubMed
    Score: 0.188
  12. Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail. Sci Transl Med. 2017 Sep 20; 9(408).
    View in: PubMed
    Score: 0.182
  13. Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. Sci Transl Med. 2017 09 06; 9(406).
    View in: PubMed
    Score: 0.181
  14. Virological Control by the CD4-Binding Site Antibody N6 in Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys. J Virol. 2017 08 15; 91(16).
    View in: PubMed
    Score: 0.180
  15. Adenovirus prime, Env protein boost vaccine protects against neutralization-resistant SIVsmE660 variants in rhesus monkeys. Nat Commun. 2017 06 05; 8:15740.
    View in: PubMed
    Score: 0.178
  16. Development of novel replication-defective lymphocytic choriomeningitis virus vectors expressing SIV antigens. Vaccine. 2017 01 03; 35(1):1-9.
    View in: PubMed
    Score: 0.172
  17. Antibody Responses After Analytic Treatment Interruption in Human Immunodeficiency Virus-1-Infected Individuals on Early Initiated Antiretroviral Therapy. Open Forum Infect Dis. 2016 Apr; 3(2):ofw100.
    View in: PubMed
    Score: 0.166
  18. Transient CD4+ T Cell Depletion Results in Delayed Development of Functional Vaccine-Elicited Antibody Responses. J Virol. 2016 May; 90(9):4278-4288.
    View in: PubMed
    Score: 0.165
  19. Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection. PLoS Pathog. 2016 Mar; 12(3):e1005520.
    View in: PubMed
    Score: 0.164
  20. Production of Mucosally Transmissible SHIV Challenge Stocks from HIV-1 Circulating Recombinant Form 01_AE env Sequences. PLoS Pathog. 2016 Feb; 12(2):e1005431.
    View in: PubMed
    Score: 0.162
  21. Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys. Science. 2015 Jul 17; 349(6245):320-4.
    View in: PubMed
    Score: 0.156
  22. A multivalent clade C HIV-1 Env trimer cocktail elicits a higher magnitude of neutralizing antibodies than any individual component. J Virol. 2015 Mar; 89(5):2507-19.
    View in: PubMed
    Score: 0.150
  23. Generation and evaluation of clade C simian-human immunodeficiency virus challenge stocks. J Virol. 2015 Feb; 89(4):1965-74.
    View in: PubMed
    Score: 0.150
  24. Common features of mucosal and peripheral antibody responses elicited by candidate HIV-1 vaccines in rhesus monkeys. J Virol. 2014 Nov; 88(22):13510-5.
    View in: PubMed
    Score: 0.147
  25. Induction of HIV-1-specific mucosal immune responses following intramuscular recombinant adenovirus serotype 26 HIV-1 vaccination of humans. J Infect Dis. 2015 Feb 15; 211(4):518-28.
    View in: PubMed
    Score: 0.147
  26. Characterization and immunogenicity of a novel mosaic M HIV-1 gp140 trimer. J Virol. 2014 Sep 01; 88(17):9538-52.
    View in: PubMed
    Score: 0.145
  27. First-in-human evaluation of a hexon chimeric adenovirus vector expressing HIV-1 Env (IPCAVD 002). J Infect Dis. 2014 Oct 01; 210(7):1052-61.
    View in: PubMed
    Score: 0.143
  28. Comparison of multiple adjuvants on the stability and immunogenicity of a clade C HIV-1 gp140 trimer. Vaccine. 2014 Apr 11; 32(18):2109-16.
    View in: PubMed
    Score: 0.142
  29. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature. 2013 Nov 14; 503(7475):224-8.
    View in: PubMed
    Score: 0.139
  30. Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell. 2013 Oct 24; 155(3):531-9.
    View in: PubMed
    Score: 0.139
  31. Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001). J Infect Dis. 2013 Jan 15; 207(2):248-56.
    View in: PubMed
    Score: 0.130
  32. First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001). J Infect Dis. 2013 Jan 15; 207(2):240-7.
    View in: PubMed
    Score: 0.130
  33. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature. 2012 Jan 04; 482(7383):89-93.
    View in: PubMed
    Score: 0.122
  34. International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine. 2011 Jul 18; 29(32):5203-9.
    View in: PubMed
    Score: 0.117
  35. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med. 2010 Mar; 16(3):319-23.
    View in: PubMed
    Score: 0.108
  36. Breadth of neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigs. J Virol. 2010 Apr; 84(7):3270-9.
    View in: PubMed
    Score: 0.107
  37. Immunogenicity of recombinant Modified Vaccinia Ankara following a single or multi-dose vaccine regimen in rhesus monkeys. Vaccine. 2009 Mar 04; 27(10):1549-56.
    View in: PubMed
    Score: 0.100
  38. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature. 2009 Jan 01; 457(7225):87-91.
    View in: PubMed
    Score: 0.098
  39. Differential antigen requirements for protection against systemic and intranasal vaccinia virus challenges in mice. J Virol. 2008 Jul; 82(14):6829-37.
    View in: PubMed
    Score: 0.095
  40. Recruitment and expansion of dendritic cells in vivo potentiate the immunogenicity of plasmid DNA vaccines. J Clin Invest. 2004 Nov; 114(9):1334-42.
    View in: PubMed
    Score: 0.074
  41. Assessment of Maternal and Neonatal SARS-CoV-2 Viral Load, Transplacental Antibody Transfer, and Placental Pathology in Pregnancies During the COVID-19 Pandemic. JAMA Netw Open. 2020 12 01; 3(12):e2030455.
    View in: PubMed
    Score: 0.057
  42. A microbial expression system for high-level production of scFv HIV-neutralizing antibody fragments in Escherichia coli. Appl Microbiol Biotechnol. 2019 Nov; 103(21-22):8875-8888.
    View in: PubMed
    Score: 0.053
  43. HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design. Cell Host Microbe. 2019 08 14; 26(2):296.
    View in: PubMed
    Score: 0.052
  44. HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design. Cell Host Microbe. 2019 01 09; 25(1):59-72.e8.
    View in: PubMed
    Score: 0.050
  45. T-cell subset differentiation and antibody responses following antiretroviral therapy during simian immunodeficiency virus infection. Immunology. 2018 12; 155(4):458-466.
    View in: PubMed
    Score: 0.048
  46. First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector. J Infect Dis. 2018 07 13; 218(4):633-644.
    View in: PubMed
    Score: 0.048
  47. Corrigendum: An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2018 03 14; 555(7696):402.
    View in: PubMed
    Score: 0.047
  48. Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections. PLoS Pathog. 2018 03; 14(3):e1006860.
    View in: PubMed
    Score: 0.047
  49. Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials. Lancet. 2018 02 10; 391(10120):563-571.
    View in: PubMed
    Score: 0.046
  50. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017 07 13; 547(7662):217-221.
    View in: PubMed
    Score: 0.045
  51. Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention: A Randomized Trial. Ann Intern Med. 2016 Mar 01; 164(5):313-22.
    View in: PubMed
    Score: 0.041
  52. Vaccine delivery with microneedle skin patches in nonhuman primates. Nat Biotechnol. 2013 Dec; 31(12):1082-5.
    View in: PubMed
    Score: 0.035
  53. HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120. Proc Natl Acad Sci U S A. 2012 Jul 24; 109(30):12111-6.
    View in: PubMed
    Score: 0.032
  54. Robust vaccine-elicited cellular immune responses in breast milk following systemic simian immunodeficiency virus DNA prime and live virus vector boost vaccination of lactating rhesus monkeys. J Immunol. 2010 Dec 01; 185(11):7097-106.
    View in: PubMed
    Score: 0.028
  55. Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates. J Virol. 2005 May; 79(10):6516-22.
    View in: PubMed
    Score: 0.019
  56. Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies. J Virol. 2003 Oct; 77(19):10348-56.
    View in: PubMed
    Score: 0.017
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.